Shots:
- Eli Lilly has reported P-IIIb (TOGETHER-PsO) trial data assessing Taltz (ixekizumab) + Zepbound (tirzepatide) vs Taltz alone in 274 adults with mod. to sev. plaque psoriasis & obesity/overweight with ≥1 additional weight-related comorbid condition
- At 36wks., the trial met its 1EP with 27.1% pts reaching PASI 100 & ≥10% weight loss compared to 5.8% pts. Trial also achieved its 2EP, with Taltz + Zepbound delivering 40% relative increase in PASI 100 rates over Taltz alone (40.6% vs 29%); data to be published in the future & discussed with regulators
- Taltz is a monoclonal antibody targeting IL-17A to block its receptor interaction, while Zepbound is a dual GIP/GLP-1 receptor agonist
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports P-III (LIBRETTO-432) Trial Findings on Retevmo (Selpercatinib) in RET Fusion-Positive NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
